Deferoxamine

🧮 Dose calculator

Acute iron poisoning · Regimen source: FDA Deferoxamine · 2.1

• • Adults and children. IM for patients not in shock; IV only in cardiovascular collapse at ≤15 mg/kg/h (later doses up to 125 mg/h). Subsequent 500 mg doses by clinical response. FDA Deferoxamine · 2.1FDA Deferoxamine · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Deferoxamine · 8.1

  “Risk Summary There are no available data on Deferoxamine Mesylate for Injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriages or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Deferoxamine · 8.2

  “Because of the potential for serious adverse reactions in the breastfed child, advise patients not to breastfeed during treatment with Deferoxamine Mesylate for Injection, and for one week after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Deferoxamine · 8.4

  “Safety and effectiveness in pediatric patients 3 years of age and older have been established for the treatment of acute iron intoxication and for the treatment of transfusional iron overload in patients with chronic anemia.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Deferoxamine · 8.5

  “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Deferoxamine · 8.3

  “Contraception Females Deferoxamine Mesylate for Injection can cause embryo-fetal harm when administered to pregnant women [see Use in Specific Populations ( 8.1 )].”